Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1420007

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Mental Illness
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they will take to support those who are clinically extremely vulnerable who have been shielding during the COVID-19 pandemic and are now suffering with their mental health.
tabling member printed	Lord Mendelsohn
uin	HL6002
answer	answer is ministerial correction date of answer 11/02/2022 answer text <p>People previously considered clinically extremely vulnerable are advised to follow general guidance while considering any additional precautions to reduce the risk of infection. For those who require support for their mental health, advice is available from general practitioners or via online only self-care resources such as Every Mind Matters, Let’s Talk Loneliness and the Hub of Hope, which provides information on local services. Patients can also self-refer into local talking and psychological therapy services. The NHS Volunteer Responders scheme can also provide telephone support or help with collecting shopping, medication or other essential supplies.</p> answering member printed Lord Kamall question first answered 11/02/2022 12:40:32 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1420008

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many clinically extremely vulnerable people have received their fourth dose of the COVID-19 vaccine.
tabling member printed	Lord Mendelsohn
uin	HL6003
answer	answer is ministerial correction date of answer 11/02/2022 answer text <p>The data regarding fourth doses of COVID-19 vaccines is not yet available in the format requested as it is currently being collated and centrally validated.</p><p> </p> answering member printed Lord Kamall question first answered 11/02/2022 12:37:50 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1420009

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many (1) immunocompromised, or (2) immunosuppressed, people have received their fourth dose of the COVID-19 vaccine.
tabling member printed	Lord Mendelsohn
uin	HL6004
answer	answer is ministerial correction date of answer 11/02/2022 answer text <p>The data regarding fourth doses of COVID-19 vaccines is not yet available in the format requested as it is currently being collated and centrally validated.</p> answering member printed Lord Kamall question first answered 11/02/2022 12:40:10 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1420010

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many courses of (1) antiviral, and (2) monoclonal, antibody treatments for COVID-19 are (a) currently held by NHS England, and (b) secured via new contracts.
tabling member printed	Lord Mendelsohn
uin	HL6005
answer	answer is ministerial correction date of answer 15/02/2022 answer text <p>In December 2021, we announced the procurement of 4.25 million courses of oral antivirals, in addition to 730,000 courses previously procured. We have also procured 100,008 courses of the neutralising monoclonal antibody, sotrovimab.</p><p>The National Health Service has access to other therapeutics, including remdesivir and Ronapreve. We are unable to provide information on the contracted volumes for other antivirals and monoclonal antibodies and the number of courses currently held in England, as this is commercially sensitive. Hospitals and COVID Medicines Delivery Units can order stock as required.</p> answering member printed Lord Kamall question first answered 15/02/2022 13:08:50 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1420011

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many (1) immunocompromised, or (2) immunosuppressed, people have received (a) antiviral, or (b) monoclonal, antibody treatments for COVID-19.
tabling member printed	Lord Mendelsohn
uin	HL6006
answer	answer is ministerial correction date of answer 11/02/2022 answer text <p>Information on the number of doses administered to immunocompromised people is not available in the format requested. These individuals are a priority for treatments, alongside those with other clinical conditions as determined by an independent advisory group.</p><p>The neutralising monoclonal antibody Ronapreve has been available to treat patients with COVID-19 in England since September 2021. As of 6 February 2022, 86 patients have been treated through COVID Medicines Delivery Units (CMDUs). The deployment of the neutralising monoclonal antibody sotrovimab began on 20 December 2021. As of 6 February 2022, 7,246 patients have been treated through CMDUs. The deployment of the oral antiviral molnupiravir began on 16 December 2021. As of 6 February 2022, 5,787 patients have been treated through CMDUs.</p><p>As of 16 January 2022, 4,962 patients have been treated with Ronapreve in hospitals; 457 patients have been treated with sotrovimab in hospitals; and 49,966 patients have been treated with Remdesivir in all settings. As of 8 February 2022, 7,868 people have been enrolled on the PANORAMIC national study, with half the participants receiving molnupiravir treatment.</p> answering member printed Lord Kamall question first answered 11/02/2022 12:40:00 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1385980

registered interest
date	07/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunotherapy: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government why they have not yet appointed a supplier of immunoglobulin products; and when they expect to have completed the tender process.
tabling member printed	Lord Mendelsohn
uin	HL4764
answer	answer is ministerial correction date of answer 16/12/2021 answer text <p>The Department, NHS Blood and Transplant and NHS England and NHS Improvement are working to create a long-term domestic supply of plasma in England which can be used to manufacture immunoglobulins. The tender notice is due to be issued early 2022, with the aim of appointing a fractionator during that year.</p><p>The production of medicines is complex and highly regulated and materials and processes must meet rigorous safety and quality standards. Subject to the necessary regulatory approvals, we expect United Kingdom plasma sourced immunoglobulins to be available to National Health Service patients in 2024.</p> answering member printed Lord Kamall grouped question UIN HL4765 question first answered 16/12/2021 15:40:13 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1385981

registered interest
date	07/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when they expect patients to receive treatment with products made from UK plasma.
tabling member printed	Lord Mendelsohn
uin	HL4765
answer	answer is ministerial correction date of answer 16/12/2021 answer text <p>The Department, NHS Blood and Transplant and NHS England and NHS Improvement are working to create a long-term domestic supply of plasma in England which can be used to manufacture immunoglobulins. The tender notice is due to be issued early 2022, with the aim of appointing a fractionator during that year.</p><p>The production of medicines is complex and highly regulated and materials and processes must meet rigorous safety and quality standards. Subject to the necessary regulatory approvals, we expect United Kingdom plasma sourced immunoglobulins to be available to National Health Service patients in 2024.</p> answering member printed Lord Kamall grouped question UIN HL4764 question first answered 16/12/2021 15:40:13 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1385982

registered interest
date	07/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Casirivimab/imdevimab
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when Ronapreve will be available for (1) immunocompromised patients unlikely to mount a vaccine response, and (2) patients at higher risk of poorer COVID-19 outcomes prior to hospitalisation.
tabling member printed	Lord Mendelsohn
uin	HL4766
answer	answer is ministerial correction date of answer 13/12/2021 answer text <p>On 20 August 2021, the Medicines and Healthcare products Regulatory Agency approved Ronapreve (casirivimab and imdevimab) as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute COVID-19 infection. A new NHS interim clinical policy will provide access for the most vulnerable non-hospitalised patients in the community with early-stage disease from 16 December, including the immunocompromised and those patients at higher risk of poorer COVID-19 outcomes.</p><p>The current supply of Ronapreve is limited globally, therefore the clinical policy prioritises the most vulnerable patients for whom this treatment will provide the most benefit, supported by clinical evidence.</p> answering member printed Lord Kamall question first answered 13/12/2021 13:36:15 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1385190

registered interest
date	06/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the benefits of testing the antibody levels of immunosuppressed or immunocompromised individuals given the spread of the Omicron variant of COVID-19.
tabling member printed	Lord Mendelsohn
uin	HL4722
answer	answer is ministerial correction date of answer 16/12/2021 answer text <p>There are currently no plans to implement targeted antibody testing for immunocompromised patients. However, clinicians in the National Health Service can arrange antibody testing based on their assessment of clinical need. Those with a cancer diagnosis may also be able to access free antibody tests through the National Cancer COVID Survey, which aims to assess levels of protection conferred by antibodies following vaccination/infection in cancer patients.  The Joint Committee on Vaccination and Immunisation will continue to review emerging scientific evidence on the use of vaccines in those who are immunocompromised and will update its advice as necessary.</p> answering member printed Lord Kamall question first answered 16/12/2021 15:26:38 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1385191

registered interest
date	06/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Immunosuppression: Coronavirus
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to ensure people who are immunosuppressed or immunocompromised receive clear communication regarding their risk from the Omicron variant of COVID-19 and the steps they can take to mitigate that risk.
tabling member printed	Lord Mendelsohn
uin	HL4723
answer	answer is ministerial correction date of answer 10/01/2022 answer text <p>The Government issued updated public health advice on 24 December 2021 for people whose immune system means they are at higher risk of serious outcomes from COVID-19. This states that people who are immunosuppressed or immunocompromised are advised to:</p><p>- ensure they have had all of the vaccines they are eligible to receive, including their booster;</p><p>- continue to follow any condition-specific advice they may have been given by their specialist;</p><p>- work from home if they can. If they cannot work from home, they should speak to their employer about what temporary arrangements they can make to reduce the risk;</p><p>- wait until 14 days after another person’s most recent dose of a COVID-19 vaccine before being in close contact with them;</p><p>- avoid enclosed crowded spaces;</p><p>- practice social distancing if appropriate;</p><p>- ventilate their home by opening windows and doors;</p><p>- ask friends and family to take a rapid lateral flow antigen test before visiting them;</p><p>- ask home visitors to wear face coverings; and</p><p>- wash their hands regularly and avoid touching their face.</p> answering member printed Lord Kamall question first answered 10/01/2022 11:38:05 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn